Our 3-part, proprietary methodology – bioprognosisTM for kidney health – predicts risk and outcomes to promote and preserve kidney health.
With one simple blood test, clinicians receive their patients’ custom risk scores with actionable, guideline-recommended treatment steps.
1
Proprietary biomarkers
Biological factors that are clinically proven – in multiple studies – to be most prognostic for kidney disease (TNFR1, TNFR2, KIM-1).
2
Select clinical features
7 select data points from a patient’s health record (eGFR, UACR, serum calcium, HbA1c, systolic BP, platelets, AST) that are indicative of kidney/other key organ health or dysfunction.
3
Validated algorithm
Machine learning combines these diverse and proprietary data inputs to maximize their value through a patient risk score.
4
Yields a clear and actionable test report:
Risk score + guideline-recommended clinical pathway
Low
Intermediate
High
KidneyIntelX is the only bioprognostic methodology and the only option for risk assessment in adults with type 2 diabetes and with chronic kidney disease stages 1-3.
KidneyIntelX demonstrated to be a 3X better predictor of risk vs traditional kidney function measures (eGFR and UACR).
References:
1.Data from Validation Study in Subgroup with UACR available Chan L, et al. Diabetologia 2021
2.Data from CANVAS analyses; Lam D, et al. Am J Nephrology 2021
FREE EDUCATIONAL RESOURCES FOR YOUR STAFF AND PATIENTS
FREE EDUCATIONAL
RESOURCES FOR YOUR
STAFF AND PATIENTS
This valuable Guide and complementary Workbook provides simple, step-by-step guidance for how your patients can improve their kidney health in consultation with you and your staff.
This valuable Guide and complementary Workbook provides simple, step-by-step guidance for how your patients can improve their kidney health in consultation with you and your staff.
Only by starting at the earliest stages of diagnosed diabetic kidney disease – and by leveraging the only test proven to identify those select adult patients with type 2 diabetes and chronic kidney disease who are at higher to lower risk for rapid progressive decline in kidney function – will clinicians and patients reap the greatest benefits from the rest of the treatment plan.
Prognosis, not diagnosis.
Current kidney function measurements – estimated GFR and UACR – are meant to diagnose whether kidney disease is present in a given patient and at what stage. Conversely, KidneyIntelX is designed to predict whether or not an adult patient with type 2 diabetes and chronic kidney disease stages 1-3 will progress, possibly resulting in kidney failure.
In fact, KidneyIntelX has a growing body of evidence via validation, utility and economic studies, including a demonstrated 72% improvement in predicting those patients who are at high risk for rapid progressive decline in kidney function vs current standard of care.